Evidence map›Paper›PMID 37816995›Full record

ArticleSurgical endoscopy2024

Perioperative use of low dose haloperidol safely reduces episodes of postoperative nausea/vomiting and length of stay following elective minimally invasive bariatric surgery.

Priscilla Lam, Nicholas Druar, Santosh Swaminathan, Tian Sheng Ng, Shohan Shetty

Abstract read
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Priscilla LamStanley J. Dudrick Department of Surgery at Saint Mary's Hospital, 56 Franklin St., Waterbury, CT, 06706, USA. priscilla.lam@trinityhealthofne.org.ORCID 0009-0008-6945-2669
Nicholas DruarStanley J. Dudrick Department of Surgery at Saint Mary's Hospital, 56 Franklin St., Waterbury, CT, 06706, USA.
Santosh SwaminathanStanley J. Dudrick Department of Surgery at Saint Mary's Hospital, 56 Franklin St., Waterbury, CT, 06706, USA.
Tian Sheng NgStanley J. Dudrick Department of Surgery at Saint Mary's Hospital, 56 Franklin St., Waterbury, CT, 06706, USA.
Shohan ShettyStanley J. Dudrick Department of Surgery at Saint Mary's Hospital, 56 Franklin St., Waterbury, CT, 06706, USA.
University of Saint Mary · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile total intravenous anesthesia (TIVA) protocols include Dexamethasone and Ondansetron prophylaxis, bariatric patients continue to be considered at particularly high risk for postoperative nausea/vomiting (PONV). A multimodal approach for prophylaxis is recommended by the Bariatric Enhanced Recovery After Surgery (ERAS) Society however, there remains a lack of consensus on the optimal strategy to manage PONV in these patients. Haloperidol has been shown at low doses to have a therapeutic effect in treatment of refractory nausea and in PONV prophylaxis in other high risk surgical populations. We sought to investigate its efficacy as a prophylactic medication for PONV in the bariatric population and to identify which perioperative strategies were most effective at reducing episodes of PONV.

methodsAn institutional bariatric database was created by retrospectively reviewing patients undergoing elective minimally invasive bariatric procedures from 2018 to 2022. Demographic data reviewed included age, gender, preoperative body mass index (BMI), ethnicity, and primary language. Primary endpoints included patient reported episodes of PONV, total doses of Ondansetron administered, need for a second antiemetic (rescue medication), complication rate (most commonly readmission within 30 days), and length of stay. Fisher's exact test, Mann-Whitney test, and ANOVA were used to evaluate the effect of perioperative management on various endpoints.

resultsA total of 475 patients were analyzed with Haloperidol being utilized in 15.8% of all patients. Patients receiving Haloperidol were less likely to require Ondansetron outside of the immediate perioperative period (34.7% vs. 49.8%, p = 0.02), experienced less PONV (41.3% vs. 64.3%, p = 0.01) and also had a decreased median length of stay (27.3 vs. 35.8 h, p < 0.0001).

conclusionsAddition of low dose Haloperidol to Bariatric ERAS protocols decreases incidence of PONV and the need for additional antiemetic coverage resulting in a significantly shorter length of stay, increasing the likelihood of safe discharge on postoperative day 1.

Indexed as

AntiemeticsBariatric SurgeryDouble-Blind MethodHaloperidolHumansLength of StayOndansetronPostoperative Nausea and VomitingRetrospective StudiesAntiemeticsHaloperidolOndansetronAprepitantBariatric ERASBariatric outcomesBariatric surgeryHaloperidolPONVPostoperative nauseaPostoperative vomiting

Identifiers

PMID37816995
OpenAlexW4387487512

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.